



August 3, 2017

## **Cara Therapeutics to Webcast Presentation at the Canaccord Genuity 37th Annual Growth Conference**

STAMFORD, Conn., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the Canaccord Genuity 37<sup>th</sup> Annual Growth Conference on Thursday, August 10, 2017, at 8:00 a.m. ET in Boston.

A live webcast of the presentation can be accessed under "Events and Presentations" in the News & Investors section of the Company's website at [www.CaraTherapeutics.com](http://www.CaraTherapeutics.com). An archived webcast recording will be available on the Cara website for approximately 30 days.

### **About Cara Therapeutics**

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system. CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. In patients with moderate-to-severe CKD-associated pruritus, CR845 has demonstrated its potential to reduce itch and improve quality of life.

#### INVESTOR CONTACT:

Michael Schaffzin

Stern Investor Relations, Inc.

212-362-1200

[michael@sternir.com](mailto:michael@sternir.com)

#### MEDIA CONTACT:

Annie Starr

6 Degrees

973-415-8838

[astarr@6degreespr.com](mailto:astarr@6degreespr.com)

 [Primary Logo](#)

Source: Cara Therapeutics Inc.

News Provided by Acquire Media